secwatch.observer — SEC 8-K summary
======================================

Issuer:     SYNLOGIC, INC. (SYBX)
CIK:        0001527599
Form:       8-K
Filed at:   2021-09-20T23:59:59+00:00
Accession:  0001193125-21-276762
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Synlogic reports positive PKU data: SYNB1618 reduces Phe, SYNB1934 shows 2x activity
--------------------------------------------------------------------------------

- SYNB1618 showed 20% reduction in fasting plasma Phe after 14 days at 1e12 dose in Phase 2 SynPheny-1 interim analysis.
- SYNB1934 demonstrated two-fold higher activity than SYNB1618 in head-to-head Phase 1 study based on biomarkers of Phe metabolism.
- Safety profile consistent with prior studies: no serious AEs, no drug-related discontinuations; AEs mild-moderate GI.
- Company plans to complete Phase 2 SynPheny-1 with SYNB1934 arm and prepare Phase 3 program for most promising strain in 2022.
- Shares trade on Nasdaq under SYBX; data support Synthetic Biotic platform for metabolic diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527599/000119312521276762/0001193125-21-276762-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527599/000119312521276762/d234976d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-276762

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer